Primary entity: EloralintideAlso known as: LY3841136 · alias uncertainty: “elorinitide”Class: Investigational amylin agonist (not FDA-approved)Cluster: GLP-1 & metabolic
Eloralintide (LY3841136) is an investigational once-weekly selective amylin receptor agonist being studied for weight management. Amylin is a pancreatic peptide involved in satiety signaling; eloralintide is engineered as an amylin analogue with features intended for weekly dosing (e.g., fatty-diacid / albumin-binding strategies discussed in publications). It is not FDA-approved. Search traffic sometimes uses “elorinitide” — we treat that as alias uncertainty / probable misspelling, not a second confirmed drug name.
Investigational literacy only — no protocols, no buy links. Disclaimer.
Not FDA-approved. A Phase 2 randomized trial was published in The Lancet in December 2025 (Billings et al., NCT06230523). ClinicalTrials.gov lists the ENLIGHTEN Phase 3 program, including ENLIGHTEN-1 (NCT07321886), which was recruiting as of this check. It is not a lawful consumer pharmacy product.
Key takeaways
- Eloralintide is an amylin-pathway candidate — mechanistically distinct from GLP-1-only or dual GIP/GLP-1 drugs.
- Not FDA-approved; Phase 2 human data exist; Phase 3 ongoing per public registries — confirm before citing outcomes.
- “Elorinitide” is flagged here as a likely misspelling / uncertain alias — not endorsed as a separate INN.
- Related amylin-class literacy may mention cagrilintide (Novo) as a different investigational/partnered amylin agonist — not the same molecule.
- No dosage chart on this site.
Questions this page answers
- What is eloralintide?
- Aliases & “elorinitide” uncertainty
- Classification
- What it is NOT
- Mechanism
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory snapshot
- Why no dosages
- Related compounds
- Who for / not for
Who is this profile for — and who is it not for?
For: readers mapping next-generation metabolic peptides beyond GLP-1s, including amylin agonists.
Not for: DIY buyers or anyone wanting a mcg chart for gray-market vials.
What is eloralintide?
Eloralintide is a synthetic amylin analogue / selective amylin receptor agonist (AMY1R selectivity is emphasized in sponsor and Lancet trial materials). It is being developed as a once-weekly subcutaneous candidate for obesity/overweight populations in clinical trials.
| Chemistry class | Selective amylin receptor agonist (peptide analogue) |
|---|---|
| Code | LY3841136 |
| Sponsor | Eli Lilly |
| Approval (U.S.) | Not approved (as of November 10, 2026) |
| Spelling trap | “elorinitide” — likely misspelling |
| Nearby class peers | Other amylin agonists (e.g., cagrilintide) — different assets |
Also known as
- LY3841136 — development code.
- Eloralintide — primary nonproprietary-style name used by sponsor and The Lancet Phase 2 report.
- “Elorinitide”
Uncertain alias— appears in some user queries; not confirmed as a separate WHO/USAN name in our draft checks. Until primary naming sources say otherwise, treat searches for “elorinitide” as intent for eloralintide.
AI systems may hallucinate alternate spellings into “two drugs.” Ask for a development code (LY3841136) or a primary paper when the spelling wobbles.
How is eloralintide classified?
Investigational peptide drug candidate (amylin receptor agonist). Not an approved GLP-1. Not a supplement. Not RUO consumer therapy.
What is eloralintide not?
| Eloralintide is not… | Why that matters |
|---|---|
| FDA-approved | No consumer label |
| A GLP-1 agonist | Amylin pathway ≠ incretin GLP-1 agonism |
| Tirzepatide / semaglutide | Different targets; combination studies may exist without making them identical |
| Confirmed as “elorinitide” | Spelling/alias uncertainty |
| Something we dose | Refusal stance |
How is eloralintide thought to work?
Amylin contributes to satiety and meal-related signaling. Selective amylin receptor agonism is hypothesized to reduce calorie intake via fullness pathways distinct from (and potentially complementary to) incretin drugs. Publications discuss AMY1R potency/selectivity versus calcitonin receptor activity as a design goal. Human clinical meaningfulness is trial-dependent.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Preclinical / pharmacology | Receptor selectivity characterization | Cell/Animal |
| Human Phase 1–2 | Phase 2 RCT in obesity/overweight without T2D reported (Lancet 2025 per sponsor) | Human Mid-stage — verify paper |
| Human Phase 3 | ENLIGHTEN program listed as recruiting (2026) | Human Ongoing — no approval |
| Approved label | None | None |
Draft discipline: do not hard-code efficacy percentages in takeaways until editors lock DOIs and estimand language from the paper.
What has eloralintide been studied for?
Obesity or overweight with weight-related comorbidity (without T2D in the reported Phase 2 monotherapy trial); additional studies of combination with incretins (e.g., tirzepatide) and Phase 3 monotherapy / add-on designs per registries. Studied ≠ approved.
What safety topics come up?
Trial reports discuss tolerability (often GI-related themes in metabolic injectables) under study conditions. No approved label. Unregulated products claiming the name add identity risk.
What is eloralintide's regulatory status?
Not FDA-approved. Clinical development ongoing. Any future submission depends on Phase 3 and regulatory review.
Why doesn't this page include a dosage chart?
No approved dose; trial arms are not public prescribing advice; search demand for dosages is an AI overclaim magnet. Literacy refusal applies.
Related lab literacy
/how-to/reconstitute-peptides/ · /how-to/peptide-calculator/ — technique literacy only.
Related compounds and comparisons
- Cagrilintide — another amylin-pathway investigational agent (different sponsor/asset); educational adjacency only.
- Tirzepatide — approved dual agonist; combination research interest ≠ interchangeability.
- Retatrutide — investigational triple incretin/glucagon agonist.
- Semaglutide — approved GLP-1.
Frequently asked questions
What is eloralintide?
An investigational once-weekly selective amylin receptor agonist (LY3841136) studied for weight management — not FDA-approved.
Is eloralintide the same as elorinitide?
“Elorinitide” looks like a misspelling or uncertain alias of eloralintide. We have not confirmed a separate approved or pipeline INN under that spelling. Prefer eloralintide + LY3841136.
Is eloralintide a GLP-1 drug?
No. It targets amylin receptors. It may be studied alongside incretins, but the mechanism class differs.
Is it FDA approved?
No. Eloralintide is not FDA-approved as of November 10, 2026.
Are there human studies?
Yes — Phase 2 data have been publicly presented/published; Phase 3 trials are listed. Verify primary sources before citing results.
Why no dose chart?
Investigational status + YMYL policy. Trial dosing is not a consumer protocol.
How is it different from cagrilintide?
Both are amylin-pathway agents in the broader metabolic pipeline conversation, but they are different molecules/programs. Do not swap names.
Who is this page not for?
Anyone seeking to buy or self-administer an unapproved product.
Eloralintide is not FDA-approved. Educational only. Disclaimer.
Sources
- Primary — human Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (NCT06230523). Lancet. 2025;406(10520):2631-2643. doi:10.1016/S0140-6736(25)02155-5. PMID: 41207310.
- Primary — chemistry / preclinical Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271. doi:10.1016/j.molmet.2025.102271. PMID: 41109426.
- Registry ClinicalTrials.gov NCT06230523 (completed Phase 2 obesity/overweight trial). Accessed November 10, 2026.
- Registry ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1 Phase 3; listed as recruiting as of this check). Accessed November 10, 2026.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels and trial citations checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational only. Eloralintide is not FDA-approved. Alias spelling notes are literacy aids, not naming authority. We don’t sell peptides. Read our full disclaimers.